Study of AZD9829 in CD123+ Hematological Malignancies

To join this study, you must be 18 years old or older. You need to have a specific type of blood cancer (like certain forms of Leukaemia or Myelodysplastic Syndromes) that has a marker called CD123 on its cells. Importantly, your cancer must have either come back or not responded to at least one previous treatment, and there shouldn't be any other standard treatment options available for you.

You also need to be well enough to take part, meaning you can generally carry out your daily activities without too much difficulty. A doctor will check your overall health and fitness using a standard score to make sure you're suitable.

There are also some reasons why you might not be able to join. For example, if your cancer has spread to your brain or spinal cord, or if you've recently had certain other cancer treatments or stem cell transplants. People with serious ongoing infections or other uncontrolled health issues might also not be able to participate. The medical team will carefully review all your health information to see if this study is right for you.

If you join this study, you will receive the new medicine, AZD9829, directly into a vein. The study team will schedule regular visits to the hospital or clinic. These visits will involve blood tests, physical examinations, and other tests to check how you're responding to the treatment and to monitor for any side effects. The frequency of these visits might be more often at the beginning of the study and then become less frequent over time.

You will continue to receive the study treatment for as long as it is helping you and you are tolerating it well. After you stop taking the study medicine, there will be some follow-up visits or phone calls to monitor your health and any lasting effects of the treatment. The total time you might be involved with the study, including follow-up, will vary from person to person.